Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1808 results
October 2015
-
Compounds spur insulin-producing cells to replicate in the lab
-
Media ReleaseNovartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidanceSolid growth (cc[1]) in Q3 sales, core operating income, core EPS for continuing operations[2] Net sales were USD 12.3 billion (-6%, +6% cc) Operating income was USD 2.2 billion (-18%, +2% cc) Core…
-
Media ReleaseNovartis a réalisé, au troisième trimestre, une forte hausse de sa marge core (tcc) et continué de renforcer son pipeline, confirmant ainsi ses prévisions pour l'exerciceCroissance solide (tcc[1]), au T3, des ventes, du résultat opérationnel core et du BPA core des activités poursuivies[2] Chiffre d'affaires net d'USD 12,3 milliards (-6%, +6% tcc) Résultat…
-
Media ReleaseNovartis steigert die Kerngewinnmarge (kWk) im dritten Quartal kräftig, stärkt erneut die Pipeline und ist auf Kurs für die JahresprognoseSolides Wachstum (kWk[1]) im dritten Quartal beim Umsatz, operativen Kernergebnis und Kerngewinn pro Aktie der fortzuführenden Geschäftsbereiche[2]: Der Nettoumsatz beläuft sich auf USD 12,3…
-
Media ReleaseNovartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritisCosentyx (secukinumab) is recommended for approval in Europe for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients Cosentyx demonstrated rapid onset of…
-
Media ReleaseNovartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and PalobiofarmaWith four programs currently in clinical trials and five more expected to enter the clinic by the end of 2016, Novartis has rapidly built a robust portfolio of programs focused on stimulating the…
-
Clinical trials make a move toward mice
By growing human tumors in mice, NIBR develops a unique system that seeks to mimic clinical trials of cancer drugs
-
Delivering access: first launch in Kenya
Chronic diseases kill 38 million people per year worldwide; almost three-quarters of those deaths occur in low- and middle-income countries. It’s time to act.
-
Getting down to the roots of Alzheimer’s disease
Experimental treatments for Alzheimer’s disease put the amyloid cascade hypothesis to the test.
-
Stopping Alzheimer's disease before it starts
Novartis collaborates with the Banner Alzheimer’s Institute to test treatments for preventing Alzheimer’s disease.
-
Media ReleaseKenya first country to launch 'Novartis Access', expanding affordable treatment options against chronic diseasesNovartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and…
-
Featured NewsIndustry and academia collaborating to innovate for patients
We are partnering with the Friedrich Miescher Institute on more than 50 research projects to improve and extend people’s lives.
Pagination
- ‹ Previous page
- 1
- …
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- …
- 151
- › Next page